ArticleScientific reports2025
Potentiation of immune checkpoint blockade with an ITPP radiosensitizer studied with oxygen saturation measurements from photoacoustic imaging.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hypoxia in the tumor microenvironment hinders antitumor immunity. Increasing tumor oxygenation may promote T cell infiltration and tumor control by immune checkpoint blockade (ICB). We found that a radiosensitizer, myo-inositol trispyrophosphate (ITPP), caused oxygen unloading from hemoglobin in CT26 and 4T1 tumors as indicated by photoacoustic imaging (PAI). This change in hypoxia detected by PAI was correlated with strong positive correlations with CD8+ and CD4+ FoxP3- effector T cell (Teff), and negative correlations with monocyte frequencies, indicating that ITPP promoted more immunogenic tumor microenvironments in both models. Combination ITPP and ICB improved tumor control and survival in both models. Therefore, imaging ITPP-modulated tumor hypoxia with PAI was related to ICB treatment response in these studies. Future combination immunotherapy regimens may benefit from monitoring hypoxia using molecular imaging with PAI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.